Auf dieser Seite
QNCX Quince Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 14, 2026
$29,20
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$15,1052-Wochen-Tief
$910,0052-Wochen-Hoch
Marktkapitalisierung (MRQ)
$30M
P/E
-0.2
EPS
$-1.68
Ihre Abzeichen
52W-Spanne
$15–$910
Analystenbewertung
BUY
Kursziel
$75
P/E
-0.2
ROE
700.5%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
QNCX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$29.20
Marktkapitalisierung (MRQ)
$30M
P/E
-0.2
EPS
$-1.68
ROE
700.5%
Verschuldungsgrad (MRQ)
-0.0
52W-Spanne
$15–$910
QNCX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 30. Juni 2026 | 1-for-20 | Umgekehrt |
| 13. April 2026 | 1-for-10 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$-1.682021-12-31 → 2025-12-31
Freier Cashflow$-42M2019-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | QNCX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -0.25-Jahres-Durchschnitt ≈-1.9 | ≈-1.9 | · | · | |
| K/B (MRQ) | -0.85-Jahres-Durchschnitt ≈0.3 | ≈0.3 | · | · | |
| EV / EBITDA | -0.6 | · | · | · | |
| Kurs / FCF (TTM) | -0.65-Jahres-Durchschnitt ≈-3.2 | ≈-3.2 | · | · | |
| Kurs / Cashflow (TTM) | -0.65-Jahres-Durchschnitt ≈-3.2 | ≈-3.2 | · | · | |
| EV / FCF (TTM) | 1.8 | · | · | · | |
| Kurs / Materieller Buchwert (MRQ) | -0.85-Jahres-Durchschnitt ≈5.1 | ≈5.1 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | QNCX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -80.8%5-Jahres-Durchschnitt ≈-48.7% | ≈-48.7% | -103.8% | Spitzenklasse | |
| ROE | 700.5%5-Jahres-Durchschnitt ≈78.0% | ≈78.0% | -323.9% | Spitzenklasse | |
| ROIC | 341.4%5-Jahres-Durchschnitt ≈14.7% | ≈14.7% | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | QNCX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | -0.0 | · | · | · | |
| Liquiditätsgrad (MRQ) | 14.55-Jahres-Durchschnitt ≈10.6 | ≈10.6 | 1.6 | Starke Liquidität | |
| Quick Ratio | 0.15-Jahres-Durchschnitt ≈10.1 | ≈10.1 | 1.4 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-18.9%
Nächster Bericht
Nov 10, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 14, 2026 | $-12.31 | $-18.24 | 32.5% |
| 31. März 2026 | Mai 11, 2026 | $57.60 | $-52.22 | 210.3% |
| 31. Dezember 2025 | $-142.00 | $-38.52 | -268.7% | |
| 30. September 2025 | $-50.00 | $-44.15 | -13.3% | |
| 30. Juni 2025 | $-46.00 | $-51.34 | 10.4% | |
| 31. März 2025 | $-3.40 | $-2.32 | -46.5% | |
| 31. Dezember 2024 | $-0.28 | $-0.18 | -56.9% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $35M | $19M | $9M | $25M | $61M | $61M | $30M | $10M | |
| SG&A Expense | $15M | $18M | $18M | $26M | $30M | $18M | $9M | $2M | |
| Operating Expenses | $58M | $57M | $35M | $52M | $90M | $79M | $39M | $12M | |
| Operating Income | $-58M | $-57M | $-35M | $-52M | $-90M | $-79M | $-39M | $-12M | |
| Interest Expense | · | · | · | · | · | · | · | $957.0K | |
| Interest Income | $1M | $3M | $3M | $1M | $620.0K | $2M | $2M | $806.0K | |
| Other Non-op | $486.0K | $-676.0K | $-102.0K | $-997.0K | $-247.0K | $0 | $0 | · | |
| Pretax Income | $-81M | $-57M | $-32M | $-52M | $-90M | $-77M | $-37M | · | |
| Income Tax | $3M | $87.0K | $-197.0K | $-284.0K | $0 | $0 | $0 | $0 | |
| Net Income | $-84M | $-57M | $-31M | $-52M | $-90M | $-77M | $-37M | $-12M | |
| EPS (Basic) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · | |
| EPS (Diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · | |
| Shares (Basic) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · | |
| Shares (Diluted) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · | |
| EBITDA | $-58M | $-57M | $-35M | $-52M | $-90M | $-79M | $-39M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6M | $6M | $75M | $41M | $29M | $134M | $51M | $25M | |
| Short-term Investments | $12M | · | · | · | · | · | · | · | |
| Receivables | · | · | · | $0 | · | · | · | · | |
| Prepaid Expense | $5M | $3M | $2M | $4M | $5M | $4M | $6M | $868.0K | |
| Other Current Assets | $54.0K | $84.0K | $81.0K | $276.0K | $367.0K | $694.0K | $688.0K | $68.0K | |
| Current Assets | $23M | $44M | $77M | $94M | $112M | $138M | $106M | $73M | |
| PP&E (Net) | $595.0K | $315.0K | $234.0K | $393.0K | $263.0K | $427.0K | $709.0K | $283.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | $378.0K | |
| Accum. Depreciation | $844.0K | $639.0K | $507.0K | $185.0K | $959.0K | $615.0K | $283.0K | $95.0K | |
| Goodwill | · | $0 | $18M | $0 | $0 | · | · | · | |
| Intangibles | $68M | $60M | $64M | $6M | $0 | · | · | · | |
| Other Non-current Assets | $2M | $10M | $9M | $0 | $194.0K | $39.0K | $217.0K | $10.0K | |
| Total Assets | $94M | $114M | $168M | $104M | $133M | $189M | $124M | $73M | |
| Accounts Payable | $2M | $3M | $2M | $570.0K | $5M | $4M | $3M | $495.0K | |
| Accrued Liabilities | $11M | $4M | $3M | $2M | $9M | $13M | $6M | $962.0K | |
| Current Liabilities | $43M | $7M | $10M | $3M | $14M | $17M | $9M | $1M | |
| Capital Leases | $330.0K | $394.0K | $321.0K | $0 | $420.0K | $208.0K | · | · | |
| Deferred Tax | $0 | $5M | $5M | $248.0K | $0 | · | · | · | |
| Other Non-current Liabilities | $2M | $685.0K | $587.0K | $0 | · | · | · | · | |
| Total Liabilities | $129M | $84M | $83M | $3M | $15M | $17M | $9M | $1M | |
| Long-term Debt | $0 | $14M | $13M | $0 | · | · | · | · | |
| Total Debt | $18M | · | · | · | · | · | · | · | |
| Common Stock | $0 | $44.0K | $43.0K | $36.0K | $30.0K | $29.0K | $27.0K | $3.0K | |
| Paid-in Capital | $419M | $407M | · | · | · | · | · | · | |
| Retained Earnings | $-460M | $-376M | $-320M | $-288M | $-237M | $-147M | $-70M | $-33M | |
| AOCI | $6M | $-35.0K | $3M | $-289.0K | $-79.0K | $313.0K | $60.0K | $-49.0K | |
| Stockholders' Equity | $-36M | $30M | $85M | $101M | $119M | $172M | $115M | $-33M | |
| Liabilities + Equity | $94M | $114M | $168M | $104M | $133M | $189M | $124M | $73M | |
| Shares Outstanding | 278,627 | 220,009 | 42,973,215 | 36,136,480 | 30,074,412 | 29,543,222 | 26,869,413 | 3,412,366 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $142.0K | $186.0K | $322.0K | $204.0K | $344.0K | $332.0K | $188.0K | $51.0K | |
| Stock-based Comp | $5M | $5M | $5M | $17M | $30M | $14M | $2M | $155.0K | |
| Deferred Tax | $-6M | $-45.0K | $-258.0K | $284.0K | · | · | · | · | |
| Operating Cash Flow | $-41M | $-32M | $-18M | $-44M | $-63M | $-51M | $-33M | $-12M | |
| CapEx | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K | $52.0K | $55.0K | $212.0K | |
| Investing Cash Flow | $23M | $22M | $-6M | $18M | $59M | $-52M | $-18M | $-47M | |
| Stock Issued | · | · | $0 | $608.0K | $0 | · | · | · | |
| Net Stock Activity | · | · | $0 | $608.0K | · | · | · | · | |
| Financing Cash Flow | $18M | $-5M | $143.0K | $707.0K | $7M | $119M | $77M | $76M | |
| Net Change in Cash | $-403.0K | $-15M | $-24M | $-25M | $3M | $16M | $26M | · | |
| Free Cash Flow | $-42M | $-32M | $-18M | $-44M | $-63M | $-51M | $-33M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROA | -80.8% | -40.2% | -23.1% | -43.6% | -55.8% | -49.0% | -37.5% | · | |
| ROE | 700.5% | -151.4% | -37.3% | -50.4% | -71.6% | -42.7% | -30.5% | · | |
| ROIC | 341.4% | -190.3% | -40.9% | -51.4% | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.5 | 6.1 | 8.1 | 30.5 | 7.9 | 8.1 | 11.9 | · | |
| Quick Ratio | 0.1 | 5.6 | 7.8 | 29.4 | 7.5 | 7.9 | 5.8 | · | |
| Debt / Equity | -0.5 | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.64 | $0.69 | $1.98 | $2.78 | $3.94 | $5.83 | $4.30 | · | |
| Cash Flow / Share | $-0.83 | $-0.74 | $-0.49 | $-1.31 | · | · | · | · | |
| Cash / Share | $0.10 | $0.93 | $1.75 | $2.50 | $3.55 | $4.53 | $1.91 | · | |
| EPS (TTM) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-84M | $-57M | $-31M | $-52M | $-90M | $-77M | $-37M | · | |
| Market Cap | $187M | $82M | $45M | $23M | $380M | $821M | $1.51B | · | |
| Enterprise Value | $199M | · | · | · | · | · | · | · | |
| P/E | -2.0 | -1.4 | -1.2 | -0.4 | -4.2 | · | · | · | |
| P/B | -5.2 | 2.7 | 0.5 | 0.2 | 3.2 | 4.8 | 13.1 | · | |
| P / Tangible Book | · | · | 11.9 | 0.2 | 3.2 | 4.8 | · | · | |
| P / Cash Flow | -4.5 | -2.6 | -2.5 | -0.5 | -6.0 | -16.1 | -45.3 | · | |
| P / FCF | -4.5 | -2.6 | -2.4 | -0.5 | -6.0 | -16.1 | -45.3 | · | |
| EV / EBITDA | -3.4 | · | · | · | · | · | · | · | |
| EV / FCF | -4.8 | · | · | · | · | · | · | · | |
| Earnings Yield | -50.1% | -70.0% | -80.0% | -241.8% | -24.0% | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $5M | $7M | $13M | $8M | $7M | $8M | $6M | $5M | $4M | $4M | $3M | $1M | $1M | $3M | $3M | $2M | |
| SG&A Expense | $17M | $4M | $4M | $3M | $3M | $5M | $4M | $4M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | |
| Operating Expenses | $80M | $15M | $19M | $13M | $10M | $15M | $12M | $6M | $28M | $11M | $10M | $6M | $6M | $13M | $6M | $8M | |
| Operating Income | $-80M | $-15M | $-19M | $-13M | $-10M | $-15M | $-12M | $-6M | $-28M | $-11M | $-10M | $-6M | $-6M | $-13M | $-6M | $-8M | |
| Interest Income | $584.0K | $160.0K | $227.0K | $300.0K | $311.0K | $406.0K | $536.0K | $683.0K | $823.0K | $887.0K | $1M | $959.0K | $805.0K | $700.0K | $536.0K | $315.0K | |
| Other Non-op | $152.0K | $2M | $660.0K | $-58.0K | $-29.0K | $-87.0K | $-518.0K | $150.0K | $91.0K | $-399.0K | $467.0K | $-216.0K | $-107.0K | $-246.0K | $204.0K | $-616.0K | |
| Pretax Income | · | · | · | · | · | $-15M | · | · | · | $-11M | · | · | · | · | · | · | |
| Income Tax | $75.0K | $-5M | $3M | $-46.0K | $67.0K | $47.0K | $7.0K | $13.0K | $36.0K | $31.0K | $51.0K | $0 | $0 | $-248.0K | $0 | $0 | |
| Net Income | $-75M | $36M | $-39M | $-13M | $-16M | $-15M | $-12M | $-5M | $-28M | $-11M | $-9M | $-5M | $-5M | $-12M | $-6M | $-8M | |
| EPS (Basic) | $-12.31 | $3.60 | $-0.75 | $-0.25 | $-68.75 | $-3.42 | $-0.28 | $-0.13 | $-0.64 | $-0.26 | $-0.21 | $-0.15 | $-0.14 | $-0.34 | $-0.09 | $-0.22 | |
| EPS (Diluted) | $-12.31 | $2.88 | $-0.75 | $-0.25 | $-68.75 | $-3.42 | $-0.28 | $-0.13 | $-0.64 | $-0.26 | $-0.21 | $-0.15 | $-0.14 | $-0.34 | $-0.09 | $-0.22 | |
| Shares (Basic) | 6,132,845 | 9,120,267 | · | 53,951,371 | 233,431 | 4,394,119 | · | 43,164,136 | 43,096,374 | 43,010,212 | · | 36,073,040 | 35,917,592 | 35,855,200 | · | 35,612,749 | |
| Shares (Diluted) | 6,132,845 | 9,190,354 | · | 53,951,371 | 233,431 | 4,394,119 | · | 43,164,136 | 43,096,374 | 43,010,212 | · | 36,073,040 | 35,917,592 | 35,855,200 | · | 35,612,749 | |
| EBITDA | $-80M | $-15M | · | $-13M | $-10M | $-15M | · | $-6M | $-28M | $-11M | · | $-6M | $-6M | $-13M | · | $-8M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $116M | $18M | $6M | $6M | $17M | $8M | $6M | $48M | $59M | $68M | · | $21M | $21M | $42M | · | $22M | |
| Short-term Investments | $0 | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables | · | · | · | · | · | · | · | · | · | · | · | $500.0K | · | · | · | · | |
| Prepaid Expense | $7M | $7M | $5M | $3M | $3M | $2M | $3M | $4M | $4M | $3M | $2M | $1M | $983.0K | $2M | $4M | $4M | |
| Other Current Assets | $393.0K | $24.0K | $54.0K | $96.0K | $55.0K | $32.0K | $84.0K | $55.0K | $79.0K | $48.0K | $81.0K | $92.0K | $143.0K | $179.0K | $276.0K | $336.0K | |
| Current Assets | $123M | $26M | $23M | $29M | $37M | $34M | $44M | $52M | $63M | $70M | $77M | $85M | $89M | $92M | $94M | $98M | |
| PP&E (Net) | $506.0K | $550.0K | $595.0K | $616.0K | $573.0K | $448.0K | $315.0K | $208.0K | $246.0K | $234.0K | $234.0K | $5.0K | $6.0K | $6.0K | $393.0K | $375.0K | |
| Accum. Depreciation | $882.0K | $856.0K | $844.0K | $807.0K | $777.0K | $691.0K | $639.0K | $667.0K | $566.0K | $530.0K | $507.0K | $13.0K | $12.0K | $12.0K | $185.0K | $159.0K | |
| Goodwill | · | · | · | $0 | · | · | $0 | $0 | $0 | $17M | $18M | $0 | $0 | $0 | $0 | $0 | |
| Intangibles | $0 | $0 | $68M | $68M | $68M | $62M | $60M | $65M | $62M | $62M | $64M | $0 | $0 | $0 | $6M | $6M | |
| Other Non-current Assets | $78.0K | $78.0K | $2M | $12M | $11M | $10M | $10M | $10M | $9M | $8M | $9M | · | · | · | $0 | $17.0K | |
| Total Assets | $124M | $27M | $94M | $110M | $117M | $107M | $114M | $127M | $135M | $159M | $168M | $85M | $89M | $93M | $104M | $110M | |
| Accounts Payable | $5M | $5M | $2M | $3M | $2M | $3M | $3M | $2M | $2M | $2M | $2M | $409.0K | $353.0K | $2M | $570.0K | $1M | |
| Accrued Liabilities | $4M | $3M | $11M | $5M | $6M | $5M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $1M | $2M | $4M | |
| Current Liabilities | $8M | $9M | $43M | $26M | $7M | $8M | $7M | $5M | $10M | $10M | $10M | $2M | $2M | $3M | $3M | $5M | |
| Capital Leases | $0 | $293.0K | $330.0K | $359.0K | $387.0K | $383.0K | $394.0K | $450.0K | $453.0K | $480.0K | $321.0K | · | · | · | $0 | $34.0K | |
| Deferred Tax | · | · | $0 | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $5M | $0 | $0 | $0 | $248.0K | $248.0K | |
| Other Non-current Liabilities | $716.0K | $1M | $2M | $778.0K | $745.0K | $716.0K | $685.0K | $643.0K | $609.0K | $599.0K | $587.0K | · | · | · | $0 | · | |
| Total Liabilities | $16M | $11M | $129M | $109M | $105M | $89M | $84M | $82M | $88M | $85M | $83M | $2M | $2M | $3M | $3M | $5M | |
| Long-term Debt | · | · | $0 | $0 | $17M | $15M | $14M | $15M | $14M | $14M | $13M | · | · | · | $0 | · | |
| Total Debt | $0 | $0 | · | $18M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $1.0K | $14.0K | $55.0K | $54.0K | $53.0K | $44.0K | $44.0K | $43.0K | $43.0K | $43.0K | $43.0K | $36.0K | $36.0K | $36.0K | $36.0K | $36.0K | |
| Paid-in Capital | $460M | $436M | $419M | $416M | $413M | $408M | $407M | · | · | · | · | · | · | · | · | · | |
| Retained Earnings | $-500M | $-425M | $-460M | $-421M | $-408M | $-392M | $-376M | $-364M | $-359M | $-331M | $-320M | $-311M | $-305M | $-301M | $-288M | $-283M | |
| AOCI | $4M | $5M | $6M | $6M | $6M | $2M | $-35.0K | $3M | $1M | $2M | $3M | $516.0K | $257.0K | $38.0K | $-289.0K | $-253.0K | |
| Stockholders' Equity | $-35M | $16M | $-36M | $1M | $12M | $19M | $30M | $45M | $47M | $74M | $85M | $83M | $87M | $90M | $101M | $105M | |
| Liabilities + Equity | $124M | $27M | $94M | $110M | $117M | $107M | $114M | $127M | $135M | $159M | $168M | $85M | $89M | $93M | $104M | $110M | |
| Shares Outstanding | 1,017,063 | 13,790,794 | 55,725,291 | 54,494,965 | 53,624,180 | 44,089,142 | 44,001,643 | 43,276,606 | 43,276,606 | 43,215,233 | 42,973,215 | 36,343,632 | 36,327,995 | 36,278,433 | 36,136,480 | 36,130,306 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $41.0K | $36.0K | $39.0K | $36.0K | $35.0K | $32.0K | $16.0K | $86.0K | $44.0K | $40.0K | $304.0K | $0 | $1.0K | $17.0K | $42.0K | $40.0K | |
| Stock-based Comp | $12M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $694.0K | |
| Operating Cash Flow | $-19M | $-8M | $-10M | $-10M | $-11M | $-10M | $-8M | $-7M | $-9M | $-8M | $-6M | $-5M | $-4M | $-4M | $-6M | $-7M | |
| CapEx | $0 | $0 | $4.0K | $74.0K | $126.0K | $148.0K | $133.0K | $46.0K | $39.0K | $39.0K | $24.0K | $0 | $0 | $136.0K | $78.0K | $50.0K | |
| Investing Cash Flow | $8M | $12M | $8M | $-2M | $6M | $11M | $11M | $7M | $-5M | $9M | $5M | $4M | $-20M | $6M | $19M | $-9M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $109M | $9M | $2M | $1M | $14M | $87.0K | $0 | $-5M | $35.0K | $190.0K | $57.0K | $10.0K | $26.0K | $50.0K | $-18.0K | $-5.0K | |
| Net Change in Cash | $98M | $12M | $-643.0K | $-10M | $9M | $2M | $4M | $-5M | $-14M | $1M | $-880.0K | $-1M | $-24M | $2M | $13M | $-15M | |
| Free Cash Flow | · | $-8M | · | · | · | $-10M | · | · | · | $-8M | · | · | · | $-4M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -62.6% | 53.7% | · | -11.4% | -12.7% | -11.3% | · | -5.2% | -24.8% | -8.8% | · | -5.5% | -4.7% | -11.7% | · | -6.2% | |
| ROE | 640.0% | 209.7% | · | -58.5% | -54.7% | -32.4% | · | -8.6% | -41.4% | -13.6% | · | -5.7% | -4.9% | -12.5% | · | -6.7% | |
| ROIC | · | · | · | · | · | -80.2% | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.5 | 2.9 | · | 1.1 | 5.0 | 4.0 | · | 9.5 | 6.1 | 7.2 | · | 37.8 | 45.4 | 29.7 | · | 19.9 | |
| Quick Ratio | 13.6 | 2.1 | · | 0.2 | 2.3 | 0.9 | · | 8.8 | 5.8 | 6.9 | · | 9.5 | 10.6 | 13.6 | · | 4.4 | |
| Debt / Equity | 0.0 | 0.0 | · | 16.5 | · | · | · | · | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-34.73 | $1.14 | · | $0.02 | $0.22 | $0.42 | · | $1.04 | $1.09 | $1.72 | · | $2.29 | $2.39 | $2.49 | · | $2.89 | |
| Cash Flow / Share | · | $-0.83 | · | · | · | $-0.22 | · | · | · | $-0.19 | · | · | · | $-0.10 | · | · | |
| Cash / Share | $114.04 | $1.32 | · | $0.12 | $0.31 | $0.18 | · | $1.10 | $1.37 | $1.57 | · | $0.57 | $0.57 | $1.17 | · | $0.60 | |
| EPS (TTM) | $-10.43 | $-66.87 | · | $-72.70 | $-72.58 | $-4.47 | · | $-1.24 | $-1.26 | $-0.76 | · | $-0.72 | $-0.79 | $-1.16 | · | $-2.23 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-92M | $-33M | · | $-57M | $-49M | $-61M | · | $-53M | $-53M | $-30M | · | $-28M | $-31M | $-42M | · | $-70M | |
| Market Cap | $19M | $1M | · | $89M | $88M | $59M | · | $34M | $32M | $46M | · | $41M | $55M | $57M | · | $48M | |
| Enterprise Value | $-97M | $-17M | · | $100M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -1.7 | -0.0 | · | -0.0 | -0.0 | -0.3 | · | -0.6 | -0.6 | -1.4 | · | -1.6 | -1.9 | -1.3 | · | -0.6 | |
| P/B | -0.5 | 0.1 | · | 83.9 | 7.5 | 3.2 | · | 0.7 | 0.7 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | |
| P / Tangible Book | · | 0.1 | · | · | · | · | · | · | · | · | · | 0.5 | 0.6 | 0.6 | · | 0.5 | |
| P / Cash Flow | · | -0.2 | · | · | · | -6.1 | · | · | · | -5.5 | · | · | · | -15.9 | · | · | |
| Earnings Yield | -57.3% | -66207.9% | · | -4460.1% | -4398.8% | -336.1% | · | -159.8% | -168.0% | -71.7% | · | -64.3% | -52.5% | -74.4% | · | -167.7% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-84M | $-57M | $-31M | $-52M | $-90M |
| Verwässerte EPS | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | -0.5 | · | · | · | · |
| Liquiditätsgrad | 0.5 | 6.1 | 8.1 | 30.5 | 7.9 |
| Quick Ratio | 0.1 | 5.6 | 7.8 | 29.4 | 7.5 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-42M | $-32M | $-18M | $-44M | $-63M |
Institutionelle Eigentümer (13F) 2 Einreicher · $7.1M gesamt · Stand 31. Dezember 2025
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
2
Gehaltener Wert
$7.1M
Neue Positionen
15
Geschlossene Positionen
35
Institutionelle Aktivität — Q1 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 15 (-11 vs. Vorquartal) | 35 (+31 vs. Vorquartal) | 8 (-13 vs. Vorquartal) | 12 (+7 vs. Vorquartal) | -5.2M |
Verglichen mit Q4 2025. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6.981.450 | 2.084.015 | 98,72% | Aktien |
| TWO SIGMA ADVISERS, LP | $90.785 | 27.100 | 1,28% | Aktien |
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| David A. Lamond | 13. November 2024 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 24 Insider · 14 Führungskräfte · 14 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Dirk Thye | CEO and CMO | 23. Januar 2026 A | 739.885 | 0 | 0 | $0 |
| Christopher P. Lowe | Interim CEO, COO & CFO | 3. März 2022 A | 265.000 | 0 | 0 | $0 |
| Casey Lynch | Chief Executive Officer | 3. Januar 2022 A | 109.895 | 0 | 0 | $0 |
| Charles S. Ryan | President | 23. Januar 2026 A | 130.009 | 0 | 0 | $0 |
| Brendan Hannah | CBO, COO & CCO | 23. Januar 2026 A | 361.827 | 0 | 0 | $0 |
| Brigette Roberts | Chief Corp. Affairs Officer | 18. Mai 2026 A | · | 0 | 0 | $0 |
| Guenter Janhofer | Chief Scientific Officer | 23. Oktober 2023 A | · | 0 | 0 | $0 |
| Ted Monohon | Chief Accounting Officer & VP | 6. März 2023 S | 27.440 | 0 | 0 | $0 |
| Karen L. Smith | Chief Medical Officer | 1. Februar 2023 A | 194.690 | 0 | 0 | $0 |
| Leslie Holsinger | EVP, Preclinical Development | 6. Juni 2022 F | 148.080 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | Chief Legal & Adm. Officer | 6. Juni 2022 S | 122.500 | 0 | 0 | $0 |
| Michael J. Detke | Chief Medical Officer | 3. März 2022 A | 140.000 | 0 | 0 | $0 |
| Stephen S. Dominy | Chief Scientific Officer | 3. Januar 2022 A | 1.217.086 | 0 | 0 | $0 |
| Kristen Gafric | SVP, Legal & Administration | 6. Februar 2020 A | · | 0 | 0 | $0 |
| David Lamond | Direktor | 11. Juni 2026 A | 2.347.545 | 0 | 0 | $0 |
| Christopher J. Senner | Direktor | 11. Juni 2026 A | · | 0 | 0 | $0 |
| June Bray | Direktor | 2. Januar 2026 A | · | 0 | 0 | $0 |
| Margaret Mcloughlin | Direktor | 2. Januar 2026 A | 8.000 | 0 | 0 | $0 |
| Luca Benatti | Direktor | 26. Dezember 2025 S | 39.179 | 0 | 1 | $-173.500 |
| Rajiv Patni | Direktor | 4. Juni 2025 A | · | 0 | 0 | $0 |
| Una S Ryan | Direktor | 4. Juni 2025 A | 2.875 | 0 | 0 | $0 |
| Philip S Low | Direktor | 19. Mai 2022 A | 63.974 | 0 | 0 | $0 |
| Marwan Sabbagh | Direktor | 14. März 2022 A | · | 0 | 0 | $0 |
| Kevin Young | Direktor | 8. Juni 2020 A | 30.000 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 1 ETF
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 12.044 SH | 19. August 2026 | Täglich |
QNCX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 13 Analysten
KAUF
Median-Ziel
$69.00
+136,3%
4 30,8%
Starker Kauf
5 38,5%
Kauf
4 30,8%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
6 Analysten · 2026-09-20Mittelwert-Ziel $75.17 +157,4%
← Unter allen Zielen
Aktueller Preis $29.20
Tief$65.00
Mittelwert$75.17
Hoch$98.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| QNCX | $187M | -2.0 | · | · | 700.5% | · |
| ALGS | $58M | -3.8 | -39.5% | -1106.7% | -31.1% | · |
| ELUT | · | 0.8 | -15.0% | 434.2% | -753.4% | 53.7% |
| BYSI | · | · | · | · | 3.1% | · |
| ABVC | $53M | -5.5 | 234.3% | · | -128.2% | · |
| MCRB | $142M | 23.2 | · | 721.9% | 14.8% | · |
| ATYR | $77M | -1.0 | -19.1% | -39009.5% | -107.8% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 14, 2026